Skip to main content

DFCs for Other Viruses

Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.




SARS-CoV-2 and
Other Viruses

DFCs have the potential to treat and prevent other life-threatening viruses, including SARS-CoV-2. Preclinical and discovery efforts are ongoing including investigations on dual acting DFCs that combine influenza and SARS targeting groups.

Preclinical evidence shows DFCs engineered against the ACE2 receptor-binding region of the spike protein of SARS-COV-2 are potent and broad spectrum.

Subscribe here for updates.